International Symposium on Predictive Oncology and Intervention Strategies Plenary Program

See also: Symposia Overview and Topics

	Sat. Feb. 7	Sun. Feb. 8	Mon. Feb. 9	Tue. Feb. 10
AM	Molecular Oncogenesis	Predictive Markers & Validation	Immunobiology	Prevention & Intervention
1.	Who gets cancer? B Nexo (University of Aarhus, Aarhus)	HPV & other cofactors in cervical cancer EL Franco (McGill University, Montreal)	Stromal cell-derived factor & hematological stem cells HE Broxmeyer (Indiana University School of Medicine, Indianapolis)	Markers of chromosome damage in humans S Bonassi (IST, Genoa)
2.	Ubiquitin: signal & proteosome inhibition J Pouyssegur (Institute of Signaling, Developmental Biology, & Cancer Research, Nice)	Oxidative stress & lipid peroxidation-derived DNA lesions in inflammation driven carcinogenesis H Bartsch (DKZ, Heidelberg)	T cell differentiation in allogeneic bone marrow chimeras K Onoe (Institute for Genetic Medicine, Sapporo)	Initiation of apoptosis & suppression of angiogenesis A-NT Kong ( EOHSI-UMDNJ, Piscataway, NJ )
3.	Telomere & telomerase in human cancer WC Hahn (Harvard Medical School)	Molecular changes in preneoplastic lesions A Gazdar (UTSW, Dallas)	New strategy for intractable diseases including malignant tumors S Ikehara (Kansai Medical University, Osaka)	Molecular targets for colon cancer AG Dalgleish (University London School Medicine, St. George's Hospital, London)
4.	Human adult stem cell markers: lack of gap junctional communication & Oct 4 expression: “hallmarks” in cancer cause & prevention JE Trosko (Michigan State University, East Lansing)	P53 gene mutations in human skin cancers A Sarasin (IGR, Villejuif)	Immunological recovery following hematopoietic stem cells transplant for leukemia & lymphoma N Kapoor (University of Southern California, Los Angeles)	Integrating proteomic & functional genomic technologies in discovery-driven translational breast cancer research JE Celis (Danish Centre for Translational Breast Cancer Research, Copenhagen)
5.	From genes to treatments targeted on oncogenic events L Degos (St Louis, Paris)	HER-2/neu expression & prognosis in breast cancer J Horton (H Lee Moffitt Cancer Center, Tampa, FL)	Lessons from the first decade & a half of gene therapy RM Blaese (Human Therapeutics, Newtown, PA)	Emerging concepts for chemoprevention of prostate cancer R Lieberman (NCI, Rockville, MD)
6.			Anti-cytokine (anti-IL-6 receptor) therapy of cronic inflammations and hemopoietic malignancies T Kishimoto (Kansai Medical University, Osaka)
PM	Keynote		Keynote	Keynote
PM	Hereditary predisposition to cancer HT Lynch (Creighton University, Omaha, NE)		Robert Good memorial program: the three E's of cancer immunoediting RD Schreiber (Washington University, St Louis MO)	WHO cancer control program to reduce cancer burden C Sepulveda (WHO, Geneva)
PM	Oncogenic Pathways	Risk & Assessment	Cancer Immunity
1.	Polymorphism in Metabolic Genes SJ Garte ( EOHSI-UMDNJ, Piscataway, NJ )	Screening controversies AB Miller (University of Toronto, Toronto)	Immune responses to human tumors: development of tumor vaccines CD Platsoucas (Temple University Center for Biotechnology, Philadelphia)
2.	Genomic DNA transfer from apoptotic bodies L Holmgren (Karolinska Institute, Stockholm)	Molecular models of hematologic malignancies L Luzzatto (IST, Genoa)	Recombinant cancer vaccines: design & development JD Hodge (NCI Bethesda)
3.	Gene expression predicting oncogenic pathways JR Nevins (Duke)	Microarray gene expression RR Brentani (Ludwig Institute, São Paulo)	Toll-like receptors: immunodeficiency & cancer S Haraguchi (All Children's Hospital, St Petersburg, FL)
4.	ZBRK1: A paradigm for coordinating histone deacetylation, methylation, & heterocromatin formation FJ Rauscher, III (Wistar Institute Cancer Center, Philadelphia)	Molecular indicators of tumor progression L Bubendorf (Basel)	Retroviral-related peptides: not just for immunosuppression anymore GJ Cianciolo (Duke University Medical Center, Durham)
5.		Biomarkers & disease prevention H Vainio (IARC)	Trouble in the Fas lane: Lessons learned from an “Experiment of Nature” TA Fleisher (NCI Bethesda)